BioCentury | Apr 15, 2013
Company News

KS Biomedix, Pasteur Institute deal

...characterization and clinical testing of the SMAs. KSB.L will retain commercial rights to the antibodies. KS Biomedix Holdings Plc...
BioCentury | Feb 12, 2007
Clinical News

TransMID: Development discontinued

...India; and Medison in Israel. Celtic subsidiary Xenova gained TransMID through its 2003 acquisition of KS Biomedix...
BioCentury | Feb 8, 2007
Financial News

Celtic raises $156 million, drops TransMID

...Petach Tikva, Israel) for Israel. Celtic subsidiary Xenova gained TransMID through its 2003 acquisition of KS Biomedix...
BioCentury | Mar 21, 2005
Finance

Ebb & Flow

...in the firm's new Toronto office. Previously, Midmer was on the business development side at KS BioMedix...
BioCentury | Mar 7, 2005
Company News

Protox management update

...Vancouver, B.C. Business: Cancer Hired: Fahar Merchant as VP of corporate development, formerly CTO of KS Biomedix...
BioCentury | Sep 6, 2004
Company News

Xenova, QSV Biologics Ltd. deal

...recurrent glioblastoma multiforme. The sale finishes XEN's restructuring program, which began after the company acquired KS Biomedix...
BioCentury | Sep 3, 2004
Company News

XEN sells manufacturing facility

...months following completion. The sale completes XEN's restructuring program, which began after XEN's acquisition of KS Biomedix...
BioCentury | Jul 12, 2004
Finance

Ebb & Flow

...is a modified diphtheria toxin conjugated to transferrin that XEN obtained through its acquisition of KS Biomedix...
BioCentury | Jul 8, 2004
Clinical News

Xenova starts glioblastoma Phase III

...XEN gained TransMID, a modified diphtheria toxin conjugated to transferrin , through its acquisition of KS Biomedix...
BioCentury | May 17, 2004
Clinical News

TransMID regulatory update

...Xenova gained TransMID, a modified diphtheria toxin conjugated to transferrin , through its acquisition of KS Biomedix Holdings plc...
Items per page:
1 - 10 of 121
BioCentury | Apr 15, 2013
Company News

KS Biomedix, Pasteur Institute deal

...characterization and clinical testing of the SMAs. KSB.L will retain commercial rights to the antibodies. KS Biomedix Holdings Plc...
BioCentury | Feb 12, 2007
Clinical News

TransMID: Development discontinued

...India; and Medison in Israel. Celtic subsidiary Xenova gained TransMID through its 2003 acquisition of KS Biomedix...
BioCentury | Feb 8, 2007
Financial News

Celtic raises $156 million, drops TransMID

...Petach Tikva, Israel) for Israel. Celtic subsidiary Xenova gained TransMID through its 2003 acquisition of KS Biomedix...
BioCentury | Mar 21, 2005
Finance

Ebb & Flow

...in the firm's new Toronto office. Previously, Midmer was on the business development side at KS BioMedix...
BioCentury | Mar 7, 2005
Company News

Protox management update

...Vancouver, B.C. Business: Cancer Hired: Fahar Merchant as VP of corporate development, formerly CTO of KS Biomedix...
BioCentury | Sep 6, 2004
Company News

Xenova, QSV Biologics Ltd. deal

...recurrent glioblastoma multiforme. The sale finishes XEN's restructuring program, which began after the company acquired KS Biomedix...
BioCentury | Sep 3, 2004
Company News

XEN sells manufacturing facility

...months following completion. The sale completes XEN's restructuring program, which began after XEN's acquisition of KS Biomedix...
BioCentury | Jul 12, 2004
Finance

Ebb & Flow

...is a modified diphtheria toxin conjugated to transferrin that XEN obtained through its acquisition of KS Biomedix...
BioCentury | Jul 8, 2004
Clinical News

Xenova starts glioblastoma Phase III

...XEN gained TransMID, a modified diphtheria toxin conjugated to transferrin , through its acquisition of KS Biomedix...
BioCentury | May 17, 2004
Clinical News

TransMID regulatory update

...Xenova gained TransMID, a modified diphtheria toxin conjugated to transferrin , through its acquisition of KS Biomedix Holdings plc...
Items per page:
1 - 10 of 121